Global virtual twin company Dassault Systemes has completed its acquisition of ArisGlobal and is speeding up efforts to build an integrated AI platform that links science, medicine and patients by combining life sciences and healthcare capabilities.
Dassault Systemes said it expects the ArisGlobal acquisition to help it make its vision more concrete by accelerating new drug discovery and improving therapies and decision-making, raising people's quality of life.
With the acquisition, Dassault Systemes expands its business scope and will build an AI-native integrated platform connecting scientific discovery, clinical development, manufacturing and real-world patient treatment outcomes. The company has a strategy of combining AI, science, virtual twins and deep expertise within 3D UNIV+RSES to provide context needed for AI and help turn data into actionable insights.
Pascal Daloz (파스칼 달로즈), chief executive officer and chairman of Dassault Systemes, said, "Dassault Systemes' life sciences portfolio is connected as one within 3D UNIV+RSES. It connects the full drug lifecycle into a single AI-native enterprise platform so discovery, learning and improvement continue. As each stage is linked and informs the others, the value of every stage rises. Scientific models become more sophisticated, clinical trials are conducted based on richer information, and manufacturing becomes more flexible in responding to change. Patient treatment outcomes will also contribute to continuously improving future innovation."